AU2013203825B2 - Composition for the treatment of inflammatory and immune disorders - Google Patents

Composition for the treatment of inflammatory and immune disorders Download PDF

Info

Publication number
AU2013203825B2
AU2013203825B2 AU2013203825A AU2013203825A AU2013203825B2 AU 2013203825 B2 AU2013203825 B2 AU 2013203825B2 AU 2013203825 A AU2013203825 A AU 2013203825A AU 2013203825 A AU2013203825 A AU 2013203825A AU 2013203825 B2 AU2013203825 B2 AU 2013203825B2
Authority
AU
Australia
Prior art keywords
pharmaceutically acceptable
derivative
acceptable salt
inflammatory
glycine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013203825A
Other languages
English (en)
Other versions
AU2013203825A1 (en
Inventor
Paul Frederick Turner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EaglePharma Pty Ltd
Original Assignee
EaglePharma Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012901301A external-priority patent/AU2012901301A0/en
Application filed by EaglePharma Pty Ltd filed Critical EaglePharma Pty Ltd
Priority to AU2013203825A priority Critical patent/AU2013203825B2/en
Publication of AU2013203825A1 publication Critical patent/AU2013203825A1/en
Application granted granted Critical
Publication of AU2013203825B2 publication Critical patent/AU2013203825B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2013203825A 2012-04-02 2013-04-02 Composition for the treatment of inflammatory and immune disorders Active AU2013203825B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2013203825A AU2013203825B2 (en) 2012-04-02 2013-04-02 Composition for the treatment of inflammatory and immune disorders

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU2012901301A AU2012901301A0 (en) 2012-04-02 Treatment of inflammatory and immune disorders
AU2012901301 2012-04-02
PCT/GB2013/050865 WO2013150292A1 (en) 2012-04-02 2013-04-02 Composition for the treatment of inflammatory and immune disorders
AU2013203825A AU2013203825B2 (en) 2012-04-02 2013-04-02 Composition for the treatment of inflammatory and immune disorders

Publications (2)

Publication Number Publication Date
AU2013203825A1 AU2013203825A1 (en) 2013-10-17
AU2013203825B2 true AU2013203825B2 (en) 2015-12-17

Family

ID=48184233

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013203825A Active AU2013203825B2 (en) 2012-04-02 2013-04-02 Composition for the treatment of inflammatory and immune disorders

Country Status (8)

Country Link
US (1) US9387218B2 (enExample)
EP (1) EP2836208B1 (enExample)
JP (1) JP6188784B2 (enExample)
CN (1) CN104427982B (enExample)
AU (1) AU2013203825B2 (enExample)
CA (1) CA2869243C (enExample)
MX (1) MX355103B (enExample)
WO (1) WO2013150292A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018051154A1 (en) * 2016-09-15 2018-03-22 Perscellmed Roth & Partner Compound of zinc salicylate and sulphur combination as a novel treatment for asthma and copd

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030118672A1 (en) * 2001-07-23 2003-06-26 Nutrastar Methods for treating joint inflammation, pain, and loss of mobility
US20030185904A1 (en) * 2002-03-26 2003-10-02 Reynolds Peter L. Compositions and methods directed towards sore muscles and joints
US20060029647A1 (en) * 2004-02-09 2006-02-09 Friesen Kim G Composition and method for use in cartilage affecting conditions
US20060251750A1 (en) * 2002-09-30 2006-11-09 Tabor Aaron T Soy formulations and their use in skin care
US20070020218A1 (en) * 2005-07-21 2007-01-25 Eileen Richardson Composition and method for the treatment of psoriasis
US20070218042A1 (en) * 2006-03-17 2007-09-20 Khaled F M Nutrient compositions for the treatment and prevention of inflammation and disorders associated therewith
WO2012045118A1 (en) * 2010-10-07 2012-04-12 Eaglepharma Pty Ltd Combination therapy for the treatment of depression and other non-infectious diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4514421A (en) 1979-08-30 1985-04-30 Herschler R J Dietary and pharmaceutical uses of methylsulfonylmethane and compositions comprising it
US20030069202A1 (en) * 2000-06-02 2003-04-10 Kern Kenneth Norman Compositions, kits, and methods for promoting defined health benefits
JP2005013124A (ja) * 2003-06-27 2005-01-20 Toyo Shinyaku:Kk 美容効果を有する食品組成物
US20050176807A1 (en) * 2004-02-09 2005-08-11 Friesen Kim G. Composition and method for use in cartilage affecting conditions
US20090110674A1 (en) * 2007-10-24 2009-04-30 Loizou Nicos C Health supplement

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030118672A1 (en) * 2001-07-23 2003-06-26 Nutrastar Methods for treating joint inflammation, pain, and loss of mobility
US20030185904A1 (en) * 2002-03-26 2003-10-02 Reynolds Peter L. Compositions and methods directed towards sore muscles and joints
US20060251750A1 (en) * 2002-09-30 2006-11-09 Tabor Aaron T Soy formulations and their use in skin care
US20060029647A1 (en) * 2004-02-09 2006-02-09 Friesen Kim G Composition and method for use in cartilage affecting conditions
US20070020218A1 (en) * 2005-07-21 2007-01-25 Eileen Richardson Composition and method for the treatment of psoriasis
US20070218042A1 (en) * 2006-03-17 2007-09-20 Khaled F M Nutrient compositions for the treatment and prevention of inflammation and disorders associated therewith
WO2012045118A1 (en) * 2010-10-07 2012-04-12 Eaglepharma Pty Ltd Combination therapy for the treatment of depression and other non-infectious diseases

Also Published As

Publication number Publication date
US9387218B2 (en) 2016-07-12
CA2869243A1 (en) 2013-10-10
US20150111850A1 (en) 2015-04-23
CN104427982B (zh) 2017-05-17
CA2869243C (en) 2021-03-16
WO2013150292A1 (en) 2013-10-10
CN104427982A (zh) 2015-03-18
MX2014011922A (es) 2015-12-03
HK1207293A1 (en) 2016-01-29
JP6188784B2 (ja) 2017-08-30
JP2015512439A (ja) 2015-04-27
EP2836208A1 (en) 2015-02-18
AU2013203825A1 (en) 2013-10-17
EP2836208B1 (en) 2019-09-25
MX355103B (es) 2018-04-05

Similar Documents

Publication Publication Date Title
US8450339B2 (en) Compositions for treatment of common cold
US20250099430A1 (en) Prevention or treatment of sleep disorders using dexmedetomidine formulation
AU775112B2 (en) Compositions and methods comprising morphine gluconate
WO2002022128A1 (en) A method of local anesthesia and analgesia
CN105327349A (zh) Nmda受体拮抗剂的医药用途及其药物组合物
US20080299207A1 (en) Methods and compositions for administration of oxybutynin
JP2005531612A (ja) ネフォパムの製剤および痛みの治療におけるその使用
WO2019038586A1 (en) PHARMACEUTICAL COMPOSITION OF MELATONIN
US8415390B2 (en) Methods and compositions for administration of oxybutynin
CN104013638A (zh) 当药黄素及其衍生物的用途
AU2013203825B2 (en) Composition for the treatment of inflammatory and immune disorders
EA009935B1 (ru) Новая синергетическая комбинация, включающая рофлумиласт и формотерол
FI4199922T3 (fi) (1r,3s)-3-((5-syano-4-fenyylitiatsol-2-yyli)karbamoyyli)syklopentaani-1-karboksyylihappo käytettäväksi hengitystietautien hoidossa
WO2021064589A1 (en) Intranasal pharmaceutical compositions of cyclobenzaprine
AU2024276277A1 (en) Pharmaceutical composition
HK1207293B (en) Composition for the treatment of inflammatory and immune disorders
CN119654145A (zh) 鼻内用巴氯芬
US20020198228A1 (en) Composition and method for the treatment of respiratory desease
KR20140145508A (ko) 암브록솔 및 레보드로프로피진을 포함하는 안정성이 개선된 경구용 액상 제제
WO2025022362A1 (en) Compositions and methods for treating dyskinesia
CN1839834A (zh) 一种防治眼疲劳及过敏的眼药
CN116509831A (zh) 含有藏红花酸或其可药用盐的外用制剂的用途
WO2021249578A2 (zh) 预防治疗哮喘或慢阻肺或过敏性疾病等的药物
JPWO2023039345A5 (enExample)
CN115998735A (zh) 一种伏乌碱在制备镇痛药物中的应用

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)